Lexaria Bioscience Corp. began developing its DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree. Lexaria is a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs.
Lexaria has also demonstrated early-stage effectiveness in improving delivery through human skin for the potential development of topically-administered products, including patches, creams and lotions.
Lexaria’s technology is currently being evaluated for improved delivery characteristics of antiviral drugs in the global fight against COVID-19.
Lexaria operates four subsidiary companies to focus on its different commercial opportunities in their respective industries: Lexaria Pharma Corp. investigating new products for hypertension, anti-viral treatments and other drug classes; Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc) investigating oral non-combusted tobacco-derived nicotine product formats; Lexaria Hemp Corp. pursuing business-to-business opportunities with cannabinoids such as cannabidiol from hemp; and Lexaria Canpharm Corp. operating a state-of-the-art Health Canada licensed laboratory capable of developing novel psychotropic cannabinoid formulations for potential commercialization in that sector where federally legal to do so. The Lexaria companies sub-license the Company’s DehydraTECH technology worldwide for the delivery of fat-soluble active molecules and drugs.
Lexaria has conducted ground-breaking studies to open doors previously closed to disruptive new delivery technology, including the possibility of potent and fast acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking. In limited human testing, Lexaria’s own research has, for instance, demonstrated nicotine in the bloodstream in as little as 1.5-4.0 minutes after oral ingestion. And, because of the improvements in delivery, DehydraTECH also opens the possibility of utilizing micro doses in accordance with evolving FDA policies related to reducing delivered quantities of substances like nicotine.
Lexaria has demonstrated in animal studies a propensity for the DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain-barrier – evidenced through gains of as much as 1,900% in animal testing, – initiating additional new patent applications, and opening possibilities for improved delivery of certain central nervous system-targeted drugs useful against Alzheimer’s Parkinson’s, and more.
Lexaria produces industry-leading research to support its novel delivery methods, having completed a successful human clinical study in 2018 evidencing statistically significant gains in cannabidiol delivery and performance, and with additional in vivo animal and/or human studies at various stages of development and execution. Lexaria’s business model depends on industry partners who license its technology for additional R&D and product development.
None of this can happen without the talented and dedicated people who have supported Lexaria’s development and growth. Lexaria’s internal and consulting team includes industry leaders, research scientists, clinicians, analytical chemists, medical schools and universities, intellectual property experts and partnering company collaborators.
Lexaria is fortunate to be the recipient of widely varying experience and knowledge from advisors who consult with the company from time to time. These experts contribute knowledge and experience on an as-needed basis in these roles that are less formal than managers or directors. Still, we benefit from their involvement and are grateful for their presence.